Search

Keywords: cardiomyopathy, hypertrophic; cardiac myosins; drug therapy; pharmacologic actions EN cardiomyopathy, hypertrophic cardiac myosins drug therapy pharmacologic actions 700 702 3 03/02/23 20230228 NES 230228 It has been 30 years since the identification of a I MYH7 i ( -myosin heavy chain mutation) as a cause of hypertrophic cardiomyopathy (HCM) in humans. How does mavacamten fit into the current treatment paradigm for obstructive HCM patients who are still symptomatic on standard medical therapy?. [Extracted from the article]

Background--Although primary percutaneous coronary intervention (pPCI) is the preferred reperfusion method for ST-segment--elevation myocardial infarction, it remains difficult to implement in many areas, and fibrinolytic therapy is still widely used. Methods and Results--We assessed 5-year mortality in patients with ST-segment-elevation myocardial infarction from the French Registry of Acute ST-Elevation or Non-ST Elevation Myocardial Infarction (FAST-MI) 2005 according to use and type of reperfusion therapy. Of 1492 patients with ST-segment-elevation myocardial infarction with a first call ≤12 hours from onset, 447 (30%) received fibrinolysis (66% prehospital; 97% with subsequent angiography, 84% with subsequent PCI), 583 (39%) had pPCI, and 462 (31%) received no reperfusion. Crude 5-year survival was 88% for the fibrinolytic-based strategy, 83% for pPCI, and 59% for no reperfusion. Adjusted hazard ratios for 5-year death were 0.73 (95% confidence interval, 0.50-1.06) for fibrinolysis versus pPCI, 0.57 (95% confidence interval, 0.36-0.88) for prehospital fibrinolysis versus pPCI, and 0.63 (95% confidence interval, 0.34-0.91) for fibrinolysis versus pPCI beyond 90 minutes of call in patients having called ≤180 minutes from onset. In propensity score-matched populations, however, survival rates were not significantly different for fibrinolysis and pPCI, both in the whole population (88% lysis, 85% pPCI) and in the population seen early (87% fibrinolysis, 85% pPCI beyond 90 minutes from call). Conclusions--In a real-world setting, on a nationwide scale, a pharmaco-invasive strategy constitutes a valid alternative to pPCI, with 5-year survival at least equivalent to that of the reference reperfusion method. [ABSTRACT FROM AUTHOR]